Ptc Therapeutics Stock Performance
| PTCT Stock | USD 69.45 1.25 1.77% |
The company owns a Beta (Systematic Risk) of 0.98, which implies possible diversification benefits within a given portfolio. PTC Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, PTC Therapeutics is expected to follow. At this point, PTC Therapeutics has a negative expected return of -0.12%. Please make sure to check PTC Therapeutics' total risk alpha, as well as the relationship between the kurtosis and day typical price , to decide if PTC Therapeutics performance from the past will be repeated at future time.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days PTC Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's fundamental indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return (1.77) | Five Day Return (5.86) | Year To Date Return (9.50) | Ten Year Return 148.39 | All Time Return 321.16 |
1 | Disposition of 8089 shares by Klein Matthew B. of PTC Therapeutics at 76.64 subject to Rule 16b-3 | 12/30/2025 |
2 | A Look At PTC Therapeutics Valuation After Strong Recent Shareholder Returns | 01/05/2026 |
3 | Disposition of tradable shares by Neil Almstead of PTC Therapeutics at 76.95 subject to Rule 16b-3 | 01/06/2026 |
4 | Insider Selling PTC Therapeutics CFO Sells 2,1 Shares of Stock | 01/09/2026 |
5 | PTC Therapeutics projects FY26 product revenue between 700M to 800M | 01/12/2026 |
6 | PTC Therapeutics Insider Sells 80,588.80 in Stock | 01/15/2026 |
7 | QRG Capital Management Inc. Takes Position in PTC Therapeutics, Inc. PTCT - MarketBeat | 01/20/2026 |
8 | PTC Therapeutics Sees Analyst Rating Upgrade to Overweigh - GuruFocus | 01/28/2026 |
9 | WCM Investment Management LLC Acquires Shares of 147,065 PTC Therapeutics, Inc. PTCT | 02/04/2026 |
10 | PTC Therapeutics drops as it pulls Translarna NDA resubmission | 02/12/2026 |
| Begin Period Cash Flow | 610.3 M | |
| Total Cashflows From Investing Activities | 44.2 M |
PTC Therapeutics Relative Risk vs. Return Landscape
If you would invest 7,560 in PTC Therapeutics on November 16, 2025 and sell it today you would lose (615.00) from holding PTC Therapeutics or give up 8.13% of portfolio value over 90 days. PTC Therapeutics is currently does not generate positive expected returns and assumes 2.1682% risk (volatility on return distribution) over the 90 days horizon. In different words, 19% of stocks are less volatile than PTC, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
PTC Therapeutics Target Price Odds to finish over Current Price
The tendency of PTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 69.45 | 90 days | 69.45 | close to 99 |
Based on a normal probability distribution, the odds of PTC Therapeutics to move above the current price in 90 days from now is close to 99 (This PTC Therapeutics probability density function shows the probability of PTC Stock to fall within a particular range of prices over 90 days) .
PTC Therapeutics Price Density |
| Price |
Predictive Modules for PTC Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as PTC Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of PTC Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
PTC Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. PTC Therapeutics is not an exception. The market had few large corrections towards the PTC Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold PTC Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of PTC Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.11 | |
β | Beta against Dow Jones | 0.98 | |
σ | Overall volatility | 2.86 | |
Ir | Information ratio | -0.05 |
PTC Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of PTC Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for PTC Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| PTC Therapeutics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 806.78 M. Net Loss for the year was (363.3 M) with profit before overhead, payroll, taxes, and interest of 1.28 B. | |
| PTC Therapeutics currently holds about 288.43 M in cash with (107.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.01. | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: EQT Life Sciences co-leads USD million Series A in Aerska to help systematically deliver RNA medicines to the brain |
PTC Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of PTC Stock often depends not only on the future outlook of the current and potential PTC Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. PTC Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 76.8 M | |
| Cash And Short Term Investments | 1.1 B |
PTC Therapeutics Fundamentals Growth
PTC Stock prices reflect investors' perceptions of the future prospects and financial health of PTC Therapeutics, and PTC Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PTC Stock performance.
| Return On Equity | -77.4 | ||||
| Return On Asset | 0.26 | ||||
| Profit Margin | 0.42 % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 4.4 B | ||||
| Shares Outstanding | 80.29 M | ||||
| Price To Earning | (5.67) X | ||||
| Price To Book | 1,743 X | ||||
| Price To Sales | 3.13 X | ||||
| Revenue | 806.78 M | ||||
| Gross Profit | 1.28 B | ||||
| EBITDA | (120.46 M) | ||||
| Net Income | (363.3 M) | ||||
| Cash And Equivalents | 288.43 M | ||||
| Cash Per Share | 4.01 X | ||||
| Total Debt | 2.47 B | ||||
| Current Ratio | 1.23 X | ||||
| Book Value Per Share | (1.95) X | ||||
| Cash Flow From Operations | (107.69 M) | ||||
| Earnings Per Share | 8.60 X | ||||
| Market Capitalization | 5.58 B | ||||
| Total Asset | 1.71 B | ||||
| Retained Earnings | (3.65 B) | ||||
| Working Capital | 784.55 M | ||||
| Current Asset | 355.95 M | ||||
| Current Liabilities | 45.39 M | ||||
About PTC Therapeutics Performance
Assessing PTC Therapeutics' fundamental ratios provides investors with valuable insights into PTC Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the PTC Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 169.62 | 161.14 | |
| Return On Tangible Assets | (0.22) | (0.23) | |
| Return On Capital Employed | (0.31) | (0.29) | |
| Return On Assets | (0.19) | (0.20) | |
| Return On Equity | 0.38 | 0.40 |
Things to note about PTC Therapeutics performance evaluation
Checking the ongoing alerts about PTC Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for PTC Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PTC Therapeutics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 806.78 M. Net Loss for the year was (363.3 M) with profit before overhead, payroll, taxes, and interest of 1.28 B. | |
| PTC Therapeutics currently holds about 288.43 M in cash with (107.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.01. | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: EQT Life Sciences co-leads USD million Series A in Aerska to help systematically deliver RNA medicines to the brain |
- Analyzing PTC Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PTC Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining PTC Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PTC Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of PTC Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PTC Therapeutics' stock. These opinions can provide insight into PTC Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.